

14 January 2025

ADDENDUM TO INVESTOR PRESENTATION DATED 18 NOVEMBER 2024

Bioxyne Limited (ASX:BXN) ("Bioxyne" or the **"Company"),** Australian life sciences, pharmaceutical and consumer health products company and owner of **Breathe Life Sciences** ("**BLS"**), is pleased to provide the following additional support to projections made in the Investor Presentation lodged with the ASX on 18 November 2024.

The investor presentation lodged on 18 November 2024 indicated that Bioxyne as part of its near-term growth strategy had a target objective of exceeding revenue guidance of A\$20 million. The Company provides the following in support of this objective;

- The Company has recorded revenue approximately \$12.5 million for the six months to 31 December 2024 (H1 FY2025).
- A new manufacturing facility is on target to be commissioned in January 2025, doubling BLS current manufacturing capacity.
- The Company now has a broad customer base in addition to contracts announced on 21 August 2024 and 24 September 2024¹.

In the Executive Summary of the investor presentation lodged on 18 November 2024 the Company noted it had an estimated \$36.5m in supply agreements for pastilles across 2 years². It should be noted that this is an estimate. Bioxyne has reasonable grounds to make this forecast, based on current performance, forward forecasts and is supported by;

- The contracts outlined in ASX announcements made on 21 August 2024 and 24 September 2024;
- Increased manufacturing capacity, strong demand and additional smaller contracts written to those noted above;
- While the revenue mix by customer may change, a CY2025 forecast indicates that this estimate should be achieved over a two year period.

This announcement has been approved for release by the Board.


For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com

² ASX Announcement 18 September 2024 – Clarifying Statement







¹ See ASX announcements dated 21 August 2024 and 24 September 2024.



Forward Looking Statements

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Announcement.

About Bioxyne Limited:

Bioxyne Limited (ASX:BXN) is an Australian life sciences and health products business. In June 2023 Bioxyne acquired BLS in an all shares transaction, becoming the parent company of Breathe Life Sciences ("BLS") and DR Watson®. The Group, which is headquartered in Sydney and has offices in London, Manchester, Prague, Brisbane, and Nagoya, manufactures and distributes novel pharmaceuticals and consumer health products globally.

About Breathe Life Sciences:

Bioxyne Limited's wholly owned subsidiary, Breathe Life Sciences (BLS), manufactures, commercializes, and distributes medical cannabis, psychedelics, novel foods and consumer health products under our own brands and for third party brands.

BLS' goal is to become the market leading Australian manufacturer of novel pharmaceuticals and medicine products derived from Cannabis, Psilocybe Cubensis, and MDMA. In Australia, BLS is licensed to manufacture MDMA and Psilocybin products for commercial supply to authorised prescribers and clinical trials in Australia and global export markets. In the UK and Europe, BLS is a market leader in the supply of CBD (Cannabidiol) and functional mushroom products to national retailers and Amazon. BLS manufactures private, white label, and under its own brands in its UK and EU facilities.

